×÷ΪÖйúµÚÈý·½¼ì²âÓëÈÏÖ¤·þÎñµÄ¿ªÍØÕߺÍÁìÏÈÕߣ¬CTI9888À˹ά¼Ó˹¼ì²âΪȫÇò¿Í»§ÌṩһվʽĥÁ·¡¢²âÊÔ¡¢Ð£×¼¡¢ÈÏÖ¤¼°ÊÖÒÕ·þÎñ¡£
·þÎñÄÜÁ¦ÒÑÖÜÈ«ÁýÕÖµ½·ÄÖ¯´ò°ç¼°Ð¬°ü¡¢Ó¤Í¯Íæ¾ß¼°¼Ò¾ÓÉúÑÄ¡¢µç×ÓµçÆ÷¡¢Ò½Ñ§¿µ½¡¡¢Ê³Îï¼°Å©²úÆ·……µÈÐÐÒµµÄ¹©Ó¦Á´ÉÏÏÂÓΡ£
ÖÜÈ«°ü¹ÜÆ·ÖÊÓëÇå¾²£¬Íƶ¯ºÏ¹æÓëÁ¢Ò죬ÕÃÏÔÆ·ÅƾºÕùÁ¦£¬ÊµÏÖ¸ü¸ßÖÊÁ¿¡¢¸ü¿µ½¡¡¢¸üÇå¾²¡¢¸üÂÌÉ«µÄ¿ÉÒ»Á¬Éú³¤¡£
Ö×ÁöÒ©ÀíѧÑо¿¡¢ÐÄѪ¹ÜϵͳÑо¿¡¢ÖÐÊàÉñ¾ÏµÍ³Ñо¿¡¢ÄÚÉøÍ¸ÏµÍ³Ñо¿¡¢Ïû»¯ÏµÍ³Ò©ÎïҩЧÆÀ¼Û¡£
Ö×ÁöÒ©ÀíѧÑо¿(Tumor Pharmacodynamics Study)
ÔËÓ÷Ö×ÓÉúÎïѧÊÖÒÕ£¬Ö×Áöϸ°ûÖê×÷ÓýºÍÌåÄÚÂãСÊóÒÆÖ²ÁöÄ£×ÓµÈһϵÁÐÖ×ÁöҩЧÆÀ¼Ûϵͳ£¬´Ó·Ö×Ó¡¢Ï¸°ûºÍÕûÌ嶯ÎïÈý¸öˮƽÖÜȫϵͳÉîÈëµØÆÀ¼ÛÁýÕÖϸ°û¶¾ÀàÒ©Îï¡¢ÐÂÉúѪ¹ÜÌìÉúÒÖÖÆ¼Á¡¢ÄÍÒ©Äæ×ª¼Á¡¢·Ö½âÓÕµ¼¼Á¡¢ÊÜÌå»ò·ÇÊÜÌåÐÍÀÒ°±ËἤøÒÖÖÆ¼ÁÖзÖ×Ó°ÐÏòÒ©ÎïµÄÁÙ´²Ç°Ò©Ð§¼°¿¹Ö×Áö×÷ÓûúÖÆÑо¿¡£
Study on molecular, cellular and whole animal, use tumor efficacy evaluation system, such as molecular biology technology, tumor cell lines culturing and nude mice transplantation model and so on, to conduct preclinical drug efficacy and anti-tumor mechanism research on molecular targeted drugs which including: cytotoxic drugs, angiogenesis inhibitors, reversal agents, differentiation inducer, receptor or non-receptor tyrosine kinase inhibitors, etc.
ÐÄѪ¹ÜϵͳÑо¿(Cardiovascular Pharmacodynamics Study)
Ö÷ÒªÕë¶ÔÖÎÁÆÐļ¡È±Ñª¡¢¿¹ÐÄÂÉʧ³£¡¢¿¹¸ßѪѹ¡¢ÒÖÖÆÑªÐ¡°åȺ¼¯ºÍÈÜѪ˨ҩÎïÒÔ¼°¿¹¶¯ÂöÖàÑùÓ²»¯ºÍ½µÑªÖ¬Ò©ÎïµÄɸѡ¼°ÁÙ´²Ç°Ò©Ð§Ñ§ÆÀ¼ÛºÍ»úÖÆÑо¿¡£
Pre-clinical dug efficacy screening of drugs which have the following effects: myocardial ischemia treatment, anti-arrhythmia, anti-high blood pressure, inhibits platelet aggregation and thrombolytic effect, anti-atherosclerotic and blood lipid-lowering.
ÖÐÊàÉñ¾ÏµÍ³Ñо¿( Central Nervous PharmacodynamicsStudy)
Õë¶ÔÏÖÔÚÁÙ´²ÑÏÖØÍþвÈËÀ࿵½¡µÄÖØ´ó¼²²¡Öз罨ÉèÁËȱѪÐÔÄÔÖз磨4¶¯Âö±ÕÈûÈ«ÄÔȱѪģ×Ó¡¢µçÄý/Ïß˨/¹â»¯Ñ§·¨ËùÖ´óÄÔÖж¯Âö±ÕÈûÒýÆðµÄ¾Ö²¿ÐÔÄÔȱѪģ×Ó£©ºÍȱÑõ-¸´Ñõ¡¢¹È°±Ëá¡¢Ñ×Ö¢Òò×ÓµÈÓÕµ¼´óÄÔÆ¤²ãÔ´úÉñ¾ÔªÏ¸°û¡¢º£ÂíÉñ¾ÔªÏ¸°û¡¢ÄÔ΢Ѫ¹ÜÄÚÆ¤Ï¸°ûËðÉËÄ£×Ó£¬½¨ÉèһϵÁк¸ÇÁË´Óø¡¢ÊÜÌå¡¢×éÖ¯¡¢ÕûÌ嶯ÎïÄ£×Óµ½Ä£Ê½»¯¶¯ÎïµÈ¶à¸öÑо¿Ë®Æ½£¬ÖÜȫϵͳµØ¶Ô¿¹È±ÑªÐÔÄÔËðÉËÒ©Îï¾ÙÐÐÁÙ´²Ç°Ò©Ð§Ñ§ÆÀ¼Û¼°×÷ÓûúÖÆÑо¿¡£
Targeted on ischemic stroke, glutamic acid, anoxia-reoxygenation inflammation factor induced cell damage model, a series of enzymes, receptors, tissues, and whole animal models have been built, and then comprehensively and systematically conduct research on preclinical drug pharmacodynamics evaluation and efficacy mechanism.
ÄÚÉøÍ¸ÏµÍ³Ñо¿(Endocrine System Pharmacodynamics Study)
Ö÷Ҫͨ¹ýÒ©ÎïºÍ/»òÒûʳÓÕµ¼µÄ¢ñÐͼ°¢òÐÍÌÇÄò²¡Ä£×Ó¼°Äö³ÝÀදÎïת»ùÒòÄ£×Ó£¬ÔËÓÃÌÇÄÍÁ¿ºÍÌåÍâÌÇÜÕø»îÐÔ¼ì²âÒªÁ졢ѪÌÇǯ¼°·Ö×ÓÉúÎïѧµÈÊÖÒÕÖÜÈ«¿ªÕ¹¿¹ÌÇÄò²¡¼°ÆäËû´úл¼²²¡Á¢ÒìÒ©ÎïµÄÁÙ´²Ç°Ò©Ð§ºÍ»úÖÆÑо¿¡£
Study of drug & food induced Type ¢ñand Type ¢òdiabetes model as well as rodents genetically modified model, use glucose tolerance, in vitro glycosidase activity detection method, blood glucose clamp and molecular biology technology to carry out comprehensive preclinical drug efficacy and mechanism research on drugs for diabetes and other metabolic diseases.
Ïû»¯ÏµÍ³Ò©ÎïҩЧÆÀ¼Û(Digestive System PharmacodynamicsStudy)
½¨É軯ѧËðÉË¡¢Ó¦¼¤ËðÉ˺ÍÃâÒßËðÉËÒýÆðµÄθ¡¢³¦À£ÑñÄ£×Ó£»ÌåÄÚ¡¢ÍâÊÓ²ìθ¡¢³¦Ô˶¯ºÍÐж¯µçλʵÑéÒªÁì¡£
Establish gastric ulcer and enterelcosis model induced by chemical damage, stress damage and immune injury.
ÆäËûϵͳҩЧÆÀ¼Û(Pharmacodynamics Study on other system)
ºôÎüϵͳҩÎïҩЧÆÀ¼Û(Respiratory system pharmacodynamics study)
Á¼ÐÔǰÏßÏÙÔöÉúÒ©ÎïҩЧÆÀ¼Û(Benign prostatic hypertrophy pharmacodynamics study)
Ƥ·ô¼²²¡Ò©Ð§Ñ§ÆÀ¼ÛÄ£×Ó(Skin disease pharmacodynamics study)
·þÎñÓÅÊÆ
²¡ÀíʵÑéÊÒ
ÌṩÇкÏGLP¹æ·¶µÄÆÊ½â¼°×éÖ¯²¡ÀíÑо¿£¬°üÀ¨Äö³ÝÀàºÍ·ÇÄö³ÝÀදÎïµÄÆÊ½â£¬×éÖ¯ÔàÆ÷µÄÈ¡²Ä¡¢°üÂñ¡¢ÇÐÆ¬¡¢Í¨ÀýȾɫ¡¢ÌØÊâȾɫ¼°ÃâÒß×éÖ¯»¯Ñ§È¾É«£¬ÖÐÓ¢ÎÄ×éÖ¯²¡ÀíѧÕï¶Ï¼°±¨¸æ
ÁÙ´²Ä¥Á·ÊÒ
ÈÏÕæ¾ÙÐж¯ÎïµÄѪҺѧ¼ì²é¡¢ÑªÉú»¯¼ì²é¡¢ÑªÄý¹¦Ð§¼ì²é¡¢¹ÇËèÐÎ̬ѧ¼ì²é¼°ÄòÒº¼ì²é¡£Ö÷ÒªÒÇÆ÷×°±¸ÓУºSiemens ADVIA 2120i¶¯ÎïÓÃÎå·ÖÀàÈ«×Ô¶¯ÑªÒºÆÊÎöÒÇ£¬Roche Cobas 6000 C501È«×Ô¶¯Éú»¯ÆÊÎöÒÇ£¬Sysmex CA-7000È«×Ô¶¯ÑªÄýÒÇ£¬AUTION MAX AX-4030ÄòÑùÆÊÎöÒÇ¡¢BD FACS CaliburÁ÷ʽϸ°ûÒÇ¡¢CHRONO-LOG 700ѪС°åȺ¼¯ÒÇ¡£
¹©ÊÔÆ·¹ÜÀíÊÒ
ÓµÓй©ÊÔÆ·¹ÜÀíÊÒ¡¢¹©ÊÔÆ·ÅäÖÆÊÒ¡¢¹©ÊÔÆ·´æ·ÅÊÒ¡£Æ¾Ö¤GLPºÍSOPµÄÒªÇó£¬ÊµÑé¶Ô¹©ÊÔÆ·¡¢±ÈÕÕÆ·¼°ÊÔÑéÏà¹ØÊÔ¼Á¡¢Ò©Æ·µÄ¹ÜÀí£¬¶Ô¹©ÊÔÆ·µÄÎüÊÕ¡¢ÉúÑÄ¡¢ÅäÖÆ¡¢ÆÊÎö¡¢·¢·Å¡¢½ÓÄɼ°¹éµµµÈ¶à¸ö»·½Ú¾ÙÐпØÖƺ͹ÜÀí¡£
ÆÊÎö²âÊÔÊÒ
ÆÊÎö²âÊÔ²¿×÷Ϊ¹«Ë¾½¹µã²¿·ÖÖ®Ò»£¬ÒÀÀµ×¨ÒµµÄ²âÊÔÍýÏë¡¢ÏȽøµÄʵÑé×°±¸(UPLC¡¢LC/MS/MS¡¢PE¶à±êλ¼ì²âÒÇ)ºÍ¶àÄêµÄÐÐÒµÁìÏÈÂÄÀú£¬ Ö÷ҪΪº£ÄÚÍâ¿Í»§Ìṩ¶¾´ú/Ò©´úÑùÆ·µÄÆÊÎö¼ì²â·þÎñ£¬²¢ÄÜÕë¶Ô¿Í»§µÄÏêϸҪÇóΪÆäÁ¿Éí¶¨×öÏàÒ˵Ľâ¾ö¼Æ»®¡£
¶¯Îï·¿
ƾ֤¹ú¼Ò±ê×¼½¨³É£¬ÓµÓÐSPF¼¶ºÍͨË×¼¶¶¯ÎïÉèÊ©ÒÔ¼°Î¢ÉúÎï¼ì²âÊÒ¡£½ÓÄÉJonson ControlsϵͳÖÇÄÜ»¯¿ØÖƶ¯ÎïÉèÊ©µÄζȡ¢Êª¶È¡¢Ñ¹²î£¬²¢ÄÜʵÏÖ¶Ô¶¯ÎïÉèÊ©¼°¸¨ÖúÉèÊ©24СʱÇå¾²¼à¿Ø¼°±¨¾¯¡£